Risk factors for breast cancer development

Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).

Breast cancer research and treatment·2008

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2005

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2003

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2000

Purchasing oncology services. Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services.

Cancer·2000

Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study.

Cancer·2026

Civic engagement and breast cancer screening participation among US citizens.

Cancer·2026

Analysis of a large osteosarcoma sequencing data set elucidates patterns of genomic alterations.

Cancer·2026

The relationship of neighborhood socioeconomic disadvantage and pretreatment cancer-related cognitive impairment in women with breast cancer: A post hoc analysis of a randomized controlled trial.

Cancer·2026

Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps.

Cancer·2026

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Cancer·2026

A Novel 7 Sialylation-Related LncRNA Signature as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026

Prediction of meningioma shrinkage after cyproterone acetate cessation.

Neuro-oncology advances·2026

Risk of colorectal cancer incidence and mortality after removals of polyps: a cohort study using the UK Biobank.

Annals of gastroenterology·2026

<i>In vivo</i> assessment of melanoma based on photoacoustic absorption and viscoelasticity imaging.

Biomedical optics express·2026

High-sensitivity Raman spectroscopy for prostate cancer detection and tissue extraction guidance.

Biomedical optics express·2026

Development and validation of a multimodal interpretable machine learning model for the identification of osteoporosis in patients with type 2 diabetes mellitus: a multicenter retrospective study.

Frontiers in endocrinology·2026

Related Experiment Videos

Risk factors for breast cancer development

Related Concept Videos

Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

Purchasing oncology services. Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services.

Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study.

Civic engagement and breast cancer screening participation among US citizens.

Analysis of a large osteosarcoma sequencing data set elucidates patterns of genomic alterations.

The relationship of neighborhood socioeconomic disadvantage and pretreatment cancer-related cognitive impairment in women with breast cancer: A post hoc analysis of a randomized controlled trial.

Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps.

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

A Novel 7 Sialylation-Related LncRNA Signature as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma.

Prediction of meningioma shrinkage after cyproterone acetate cessation.

Risk of colorectal cancer incidence and mortality after removals of polyps: a cohort study using the UK Biobank.

<i>In vivo</i> assessment of melanoma based on photoacoustic absorption and viscoelasticity imaging.

High-sensitivity Raman spectroscopy for prostate cancer detection and tissue extraction guidance.

Development and validation of a multimodal interpretable machine learning model for the identification of osteoporosis in patients with type 2 diabetes mellitus: a multicenter retrospective study.

Related Experiment Videos

Risk factors for breast cancer development

Related Concept Videos

Related Articles